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Abstract
Background: Invasive pulmonary aspergillosis (IPA) is the most common invasive fungal disease in
immunocompromised patients, and it has a 30 % mortality rate despite appropriate antifungal therapy. This
retrospective study was performed to determine risk factors for mortality in immunocompromised children with IPA.
Methods: Medical records of 45 probable/proven IPA cases diagnosed in children with hematologic/oncologic
diseases were reviewed. Selected cases were divided into the survival (n = 30) and fatality (n = 15) groups based on
survival at 12 weeks after antifungal therapy. Clinical characteristics and serum galactomannan indices (GMIs) were
compared between the two groups.
Results: Significantly more children in the fatality group were male (p = 0.044), not in complete remission of the
underlying malignancies (p = 0.016), and had received re-induction/salvage or palliative chemotherapy (p = 0.035) than
those in the survival group. However, none of these factors was significantly associated with mortality in a multivariate
analysis. Serum GMIs were higher in the fatality group than in the survival group during the entire period of antifungal
therapy, and serum GMI at 1 week after antifungal therapy was most significantly associated with mortality. A serum
GMI > 1.50 at 1 week after antifungal therapy exhibited a sensitivity and specificity of 61.5 % and 89.3 %, respectively, in
predicting mortality within 12 weeks after antifungal therapy.
Conclusions: Higher serum GMI in the early phase of antifungal therapy was associated with mortality in
immunocompromised children with IPA. These children should receive more intensive care for IPA than others.
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Background
The occurrence of invasive fungal disease (IFD) has been
increasing in children with hematologic/oncologic diseases,
and invasive aspergillosis (IA) became the most common
form of IFD after the introduction of fluconazole prophy-
laxis [1–4]. Considering that most cases of IA are invasive
pulmonary aspergillosis (IPA), IPA is the most common
form of IFD in children with hematologic/oncologic dis-
eases [5–7]. Because IPA causes a 25–35 % mortality des-
pite the introduction of new antifungal agents such as
voriconazole and echinocandins [5, 8–10], better efforts are
necessary in order to improve outcomes of immunocom-
promised children with IPA. Predicting patients at high risk
for mortality among immunocompromised children with
IPA and providing more intensive therapy for such patients
can be an effective strategy to reduce mortality in patients
with IPA.
Serum galactomannan index (GMI) has been used as a
criterion for IPA diagnosis [11, 12], and its value has
been reported in both immunocompromised adults and
children [13]. Mortality in IPA patients with persistently
elevated serum GMI was reportedly higher than in those
with negatively converted serum GMI during antifungal
therapy [14–17]. Therefore, serum GMI may be useful
to predict prognosis in immunocompromised patients
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with IPA. However, most of the studies that reported an
association between serum GMI and prognosis in IPA
patients enrolled both adults and children [16–20], and
studies including only children are scarce [21].
Hence, this study was conducted to determine clinical
or laboratory findings associated with mortality in im-
munocompromised children diagnosed with IPA. The
results of the present study can help determine the risk
for mortality among immunocompromised children with
IPA and contribute to improve outcomes in such high-
risk patients by providing more intensive therapy in the
early phase of IPA.
Methods
Study design and patients
Medical records of children (<20 years of age) with
hematologic/oncologic diseases diagnosed with IPA be-
tween April 2009 and March 2014 at Seoul St. Mary’s
Hospital, College of Medicine, The Catholic University
of Korea, Seoul, Republic of Korea, were retrospectively
reviewed. Children diagnosed with probable or proven IPA
based on the definition of IFD revised by the European
Organization for Research and Treatment of Cancer/
Invasive Fungal Infections Cooperative Group and the
National Institute of Allergy and Infectious Diseases
Mycoses Study Group (EORTC-MSG) Consensus Group
were enrolled [11]. The follow-up endpoint in the present
study was 12 weeks after initiation of antifungal therapy
[22], and the enrolled children were divided into survival
and fatality groups based on the survival at endpoint.
Clinical factors including age; gender; underlying dis-
ease and its remission state; administered therapy before
the diagnosis of IPA; previous histories of hematopoietic
cell transplantation (HCT) and IPA; duration of fever and
neutropenia; concurrent infections; and first-line and final
antifungal agents were compared between the two groups
to determine significant factors associated with 12-week
mortality in the early phase of antifungal therapy in IPA pa-
tients. Additionally, the results of chest computed tomog-
raphy (CT) and serum GMI at the initiation and at 1, 2, 3,
4, 6, 8, 10, and 12 weeks after antifungal therapy were also
compared between the two groups. This study was ap-
proved by the Institutional Review Board of the Seoul St.
Mary’s Hospital with an exemption of acquiring informed
consent (Approval No.: KC14RISI0791).
Institutional strategies for antifungal therapy
In our hospital, antifungal prophylaxis and antifungal
therapy are performed in accordance with the recom-
mendations of the committee for “Guidelines for the
Empirical Therapy of Neutropenic Fever Patients based
on Literature in Korea” [23]. Oral fluconazole prophylaxis
(3–5 mg/kg/day) was given from the beginning of anti-
cancer chemotherapy to the recovery of neutropenia. In
the cases receiving HCT, intravenous micafungin prophy-
laxis (1 mg/kg/day) was given from the beginning of pre-
HCT conditioning therapy to engraftment; subsequently,
oral fluconazole was administered up until the conclusion
of immune suppression. Empirical antifungal therapy was
provided if the fever lasted for 3–5 days in children who
were expected to have neutropenia of 7 days or longer and
who received immune suppressants after allogeneic HCT.
Chest CT was performed in children with abnormal find-
ings on chest x-ray or positive serum GMI; pre-emptive
antifungal therapy was administered regardless of fever
duration if chest CT showed abnormal findings consistent
with fungal pneumonia or the serum GMI was positive.
Galactomannan index measure
GMIs were determined using a Platelia Aspergillus EIA
kit (BIO-RAD, Marnes-la-Coquette, France) in accord-
ance with the manufacturer’s recommendations. Serum
samples showing positive GMI were re-tested for con-
firmation. Serum GMI tests were performed once or
twice a week during neutropenia in children receiving
anti-cancer chemotherapy; in children receiving HCT,
these tests were performed once or twice a week from pre-
HCT conditioning therapy to discharge from the hospital,
and then according to the attending physician’s decision
after discharge from the hospital. GMI tests for bronchoal-
veolar lavage (BAL) fluid were performed in addition to
serum GMI tests between April 2009 and March 2011 in
children who had undergone bronchoscopy.
Definition
The diagnosis of IPA was based on the patients’ host fac-
tor, clinical criteria, and mycological criteria using the
definition of IFD revised by the EORTC-MSG Consen-
sus Group in 2008, and IPA status was categorized into
possible, probable, and proven IPA [11]. The present
study included probable and proven IPA, fulfilling the
criteria recommended by the EORTC-MSG Consensus
Group. The follow-up endpoint in the present study was
defined as 12 weeks from the beginning of parenteral ad-
ministration of antifungal agents with anti-mold effect
[22]. If IPA was diagnosed one or more months after the
completion of antifungal therapy for a previous IPA, this
was included as a separate IPA case. Fever was defined
as a body temperature of 38.0 °C or higher with a tym-
panic thermometer or 37.5 °C or higher with an axillary
thermometer, and neutropenia was defined as an absolute
neutrophil count (ANC) less than 500/mm3 or an ANC
predicted to fall to less than 500/mm3 within 2–3 days of
fever onset [23]. Chest CT findings were independently
determined by two radiologists. The fatality group in-
cluded all deceased children at follow-up endpoint, since
deciding the exact cause of death in immunocompromised
patients with IPA is difficult [22]. Positive results of GMI
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in serum and BAL fluids were defined as >0.5 and >1.0, re-
spectively, based on the 4th European Conference on In-
fections in Leukemia (ECIL-4) guidelines [12]. Oftentimes,
the GMI may rise at some time after antifungal therapy
has been initiated for IPA. However, a temporal threshold
should be set, and GMI results obtained within this
threshold may be considered to be associated with the
specific IPA; in contrast, it would be difficult to state with
certainty whether the GMI result is related to the specific
IPA for results obtained beyond this threshold. In other
words, if the GMI tests positive at a prolonged period after
an IPA had been suspected and antifungal therapy initi-
ated, then it would be unclear whether the positive GMI is
actually related to the initial IPA, or to a different more re-
cent infection. In our study, we set this temporal threshold
at 1 month. Hence, only GMI studies performed within
1 month of antifungal therapy for IPA were regarded as
related to the specific IPA.
Statistical analysis
Categorical and numerical factors were compared using a
chi-square test and Mann-Whitney test, respectively,
when comparing the survival and fatality groups. A multi-
variate analysis using a binary logistic regression test was
performed for significantly different factors in the univari-
ate analysis in order to determine significant factors asso-
ciated with mortality in IPA patients. The cut-off levels of
serum GMI for predicting mortality at each time point
during antifungal therapy were determined by using a re-
ceiver operating characteristic (ROC) curve. Statistical
analysis was performed using SPSS Statistics 17.0 (SPSS
Inc., Chicago, IL, USA), and a statistical significance was
defined as a two-tailed p < 0.05.
Results
During the study period, 326 cases of parenteral antifun-
gal therapies using anti-mold agents were identified.
Among these, 64 cases (19.6 %) of possible IPA, 43 cases
(13.2 %) of probable IPA, and 2 cases (0.6 %) of proven
IPA were diagnosed. The yearly distribution of probable/
proven IPA was not significantly different during the
studied 5 years (Fig. 1). Forty-five cases of probable/
proven IPA were diagnosed in 41 children, and four chil-
dren experienced two episodes of IPA each. In these four
cases, second episodes of IPA were diagnosed at 3, 4, 14,
and 27 months after the completion of antifungal ther-
apy for the first IPA. In another child, the first IPA was
diagnosed before the study period and the second epi-
sode of IPA was diagnosed once the study had begun,
6 weeks after the completion of antifungal therapy for
the first IPA. Mean age of the enrolled 45 cases of prob-
able/proven IPA was 11.3 ± 5.1 years, and 30 patients
(66.7 %) were males. Fifteen (33.3 %) died within 12 weeks
of antifungal therapy.
Comparison of clinical characteristics between the
survival and fatality groups
Clinical characteristics were compared between the sur-
vival and fatality groups in order to find significant fac-
tors predicting mortality in IPA patients in the early
phase of antifungal therapy (Table 1). Significantly more
cases were male in the fatality compared with the sur-
vival group (p = 0.044), however, there were no signifi-
cant differences in mean age and the type of underlying
hematologic/oncologic diseases between the two groups.
Significantly more cases in the fatality group were not in
complete remission (CR) of the underlying hematologic
Fig. 1 Yearly distribution of the incidence of invasive pulmonary aspergillosis. There was no significant difference for the annual incidence of
invasive pulmonary aspergillosis during the study period (p = 0.823)
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malignancies compared with the survival group (p =
0.016), and therefore, the frequency of re-induction/
salvage and palliative chemotherapy for underlying
diseases was significantly higher in the fatality group
than in the survival group (p = 0.035). However, none
of these factors showed a significant relationship with
mortality in a multivariate analysis (Table 1). Halo
sign was the most common finding on chest CT in
both groups, and serum GMIs were positive in
76.7 % of the survival group and 93.3 % of the fatality
group (Table 1). GMIs for BAL fluid were tested in
11 cases (10 in the survival group and one in the fa-
tality group), and were positive in six cases (54.5 %)
in the survival group. Only one (16.7 %) of the six
cases with positive BAL fluid GMI showed positive
serum GMI. Aspergillus species were identified in
Table 1 Comparison of characteristics between the survival and fatality groups
Factor Survival group (n = 30) Fatality group (n = 15) p-value (univariate) p-value (multivariate)
Gender 0.044
Male 17 (56.7) 13 (86.7)
Female 13 (43.3) 2 (13.3) 0.104
Age (years) 13 (4-19) 11 (1-19) 0.111
Underlying disease 0.296
Acute myeloid leukemia 12 (40.0) 7 (46.7)
Acute lymphoblastic leukemia 13 (43.3) 4 (26.7)
Severe aplastic anemia 5 (16.7) 2 (13.3)
Undifferentiated acute leukemia 0 (0.0) 1 (6.7)
Non-Hodgkin lymphoma 0 (0.0) 1 (6.7)
Remission status of the underlying diseasea 0.016
Complete remission status 9 (36.0) 0 (0.0)
Not complete remission status 16 (64.0) 13 (100.0) 1.000
Type of preceding chemotherapy 0.035
No chemotherapy 6 (20.0) 1 (6.7)
Induction 4 (13.3) 0 (0.0) 1.000
Re-induction or salvage 9 (30.0) 9 (60.0) 0.999
Consolidation 4 (13.3) 0 (0.0) 1.000
Maintenance 1 (3.3) 0 (0.0) 1.000
Palliative 1 (3.3) 4 (26.7) 0.999
Allogeneic hematopoietic cell transplantation 5 (16.7) 1 (6.7) 1.000
Previous history of hematopoietic cell transplantation 14 (46.7) 8 (53.3) 0.673
Previous history of invasive aspergillosis 4 (13.3) 1 (6.7) 0.651
Duration of fever (days) 2 (0–10) 3 (0–17) 0.419
Duration of neutropenia at the beginning of antifungal
therapy
1.000
≤2 weeks 14 (46.7) 7 (46.7)
>2 weeks 16 (53.3) 8 (53.3)
Presence of other accompanying infections 11 (36.7) 4 (26.7) 0.502
Chest computed tomography findings
Consolidations with a halo sign 21 (70.0) 14 (93.3) 0.129
Consolidations without a halo sign 9 (30.0) 1 (6.7) 0.129
Air-crescent sign 0 (0.0) 0 (0.0) NA
Cavity 1 (3.3) 1 (6.7) 1.000
Positive serum galactomannan results 23 (76.7) 14 (93.3) 0.234
Data are median (range) or No. (%) of cases
NA not available
aThe remission status was determined in 38 children (25 in the survival group and 13 in the fatality group), except for children with severe aplastic anemia
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BAL fluid cultures in two cases (18.2 %) of the sur-
vival group, and both of these cases showed negative
BAL fluid GMI. Two children diagnosed with proven
IPA were included in the survival group; pulmonary
lobectomy was performed in both of these cases, and
Aspergillus species were proven histopathologically in
the excised lung tissue.
Thirty-one cases (68.9 %) had received anti-fungal
prophylaxis, and most of them (83.9 %) had received oral
fluconazole (Table 2). Amphotericin B deoxycholate was
administered as a first-line antifungal agent in 82.2 % of
all probable/proven IPA cases, and first-line agents were
changed to other antifungal agents in 41 cases (91.1 %) a
median of 4 days (range: 0–34) after the initiation of an-
tifungal therapy (Fig. 2). Finally, 35 cases (77.8 %) com-
pleted antifungal therapy with oral or intravenous
voriconazole. None of the patients received antifungal
combination therapy. The administration of first-line
and final antifungal agents was not significantly different
between the survival and fatality groups (Table 2). Fur-
ther, the frequency of receiving voriconazole and the
time of voriconazole therapy initiation were not signifi-
cantly different between the two groups (data not
shown). In the fatality group, the duration of fever was
significantly longer (p = 0.031) during antifungal therapy
and more patients experienced neutropenia lasting lon-
ger than 2 weeks (p = 0.033) after antifungal therapy
compared with the survival group (Table 2).
Comparison of serum galactomannan index between the
survival and fatality groups
Serum GMI was positive in 37 (82.2 %) cases. Although
piperacillin/tazobactam may cause false positive results
for serum GMI, piperacillin/tazobactam was being ad-
ministered to only seven (15.5 %) children on the diagno-
sis of IPA and the frequencies of receiving piperacillin/
tazobactam on the diagnosis of IPA were not significantly
different between cases with and without positive serum
Table 2 Antibacterial and antifungal therapy for children with probable/proven invasive pulmonary aspergillosis
Factor Survival group (n = 30) Fatality group (n = 15) p-value
Antibacterial therapy on the diagnosis of IPA 0.511
Meropenem with teicoplanin 15 (50.0) 10 (66.7)
Meropenem 7 (23.3) 2 (13.3)
Piperacillin/tazobactam with isepamicin 4 (13.3) 3 (20.0)
Cefepime 1 (3.3) 0 (0.0)
None 3 (10.0) 0 (0.0)
Anti-fungal prophylaxis 0.327
No prophylaxis 11 (36.7) 3 (20.0)
Oral fluconazole 15 (50.0) 11 (73.3)
Oral itraconazole or intravenous micafungin 4 (13.3) 1 (6.7)
First-line antifungal agents
Amphotericin B deoxycholate 28 (93.3) 9 (60.0) 0.059
Liposomal amphotericin B 1 (3.3) 2 (13.3)
Caspofungin 0 (0.0) 1 (6.7)
Itraconazole 1 (3.3) 1 (6.7)
Intravenous voriconazole 0 (0.0) 2 (13.3)
Final antifungal agents 0.657
Amphotericin B deoxycholate 1 (3.3) 1 (6.7)
Liposomal amphotericin B 2 (6.7) 1 (6.7)
Caspofungin 3 (10.0) 1 (6.7)
Itraconazole (oral) 0 (0.0) 1 (6.7)
Voriconazole (intravenous or oral) 24 (80.0) 11 (73.3)
Total duration of fever (days) 7 (1–32) 17 (1–64) 0.031
Duration of neutropenia after antifungal therapy 0.006
≤2 weeks 21 (70.0) 4 (26.7)
>2 weeks 9 (30.0) 11 (73.3)
Data are median (range) or No. (%) of cases
IPA invasive pulmonary aspergillosis
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GMI (16.2 % vs. 12.5 %, p = 1.000). Eight (21.6 %) of the
37 cases with positive serum GMI had received piperacil-
lin/tazobactam within 3 days before positive serum GMI
results were identified. On the other hand, four (50.0 %) of
the eight cases with negative serum GMI had received pi-
peracillin/tazobactam during repeated serum GMI tests.
Serum GMIs from the initiation of antifungal therapy
to 12 weeks after antifungal therapy were compared be-
tween the survival and fatality groups. Serum GMIs were
higher in the fatality group than in the survival group
during the entire period of follow-up, and the GMIs on
the initiation of antifungal therapy and at 1, 2, 6, and
8 weeks after antifungal therapy showed significant dif-
ferences between the two groups (Table 3). The fre-
quency of positive GMI was also higher in the fatality
group than in the survival group during the entire
period of follow-up with significant differences at 1, 2,
and 6 weeks after antifungal therapy. The differences in
serum GMIs at 6 and 8 weeks after antifungal therapy
were not considered clinically significant because nine
cases (60.0 %) in the fatality group had died within
6 weeks of receiving antifungal therapy. The cut-off
levels of serum GMI for predicting mortality at the
remaining time points were determined by using an
ROC curve; the respective areas under the curve at the
initiation of antifungal therapy and 1 and 2 weeks after
antifungal therapy were 0.723, 0.812, and 0.795, respect-
ively. As a result, the serum GMI at 1 week after anti-
fungal therapy was most significantly associated with
mortality, and its cut-off value predicting mortality was
1.5 with a sensitivity of 61.5 %, specificity of 89.3 %,
positive predictive value (PPV) of 72.7 %, and negative
predictive value (NPV) of 83.3 %. The trends of serum
GMI levels in the fatality group are shown in Fig. 3.
Discussion
In the present study, risk factors for mortality in im-
munocompromised children with IPA were investigated.
Male gender, neutropenia on IPA diagnosis, acute mye-
loid leukemia rather than acute lymphoblastic leukemia
as an underlying hematologic malignancy, uncontrolled
underlying malignancy, disseminated infection, accom-
panying renal dysfunction, receiving allogeneic HCT,
and pleural effusion or micronodules in chest CT had
previously been reported as risk factors for mortality in
patients with IPA [3, 10, 24–28]. Male gender, non-CR
state of underlying hematologic malignancies, and re-
ceiving re-induction/salvage or palliative chemotherapy
Fig. 2 Diagram for antifungal therapy. Amphotericin B deoxycholate was the most commonly administered first-line antifungal agent (82.2 %).
However, most of the first-line agents were changed to other agents, and voriconazole was eventually administered in 77.8 % of the cases
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were risk factors for mortality in a univariate analysis in
the present study. However, none of them were signifi-
cantly associated with mortality in a multivariate ana-
lysis. Although the duration of fever and neutropenia
was significantly longer in the fatality group compared
with the survival group in the present study, mortality
cannot be predicted by using these factors in the early
phase of antifungal therapy. The presence of halo signs
in chest CT has previously been reported as a favorable
factor for outcome in IPA patients [29]. However, this
was not the case in the present study. Chest CT halo,
which is considered an early radiologic finding of IPA
[30, 31], was observed in 93.3 % of the cases in the fatal-
ity group in the present study; therefore, this represented
an early diagnosis of IPA in the children enrolled in the
present study, even in the fatality group. Accordingly, in
the present study, mortality would be expected to be af-
fected by the status of the patients’ underlying diseases
and the degree of response to antifungal therapy rather
than by a delayed diagnosis of IPA. In addition, the fact
that there were no significant differences in first-line and
final antifungal agents between the survival and fatality
groups shows that a differentiated and more intensive
antifungal therapy was not administered to children with
IPA at a high risk for mortality.
The association between a high serum GMI on the diag-
nosis of IPA and poor outcomes and increased mortality
in IPA patients has been previously reported [18, 32].
Rohrlich et al. demonstrated that serum GMI is useful for
diagnosing IPA in children, and reported a relationship
between high serum GMI on the diagnosis of IPA and
increased mortality [21]. IPA patients with persistently
positive serum GMI levels during antifungal therapy also
showed higher mortality compared with those with nega-
tive conversion of serum GMI [14–17]. In addition, the
degree of reduction of serum GMI within 1 week after the
diagnosis of IPA was reported to be related to mortality
[20, 33], and the increase of serum GMI by one or more
in 1 or 2 weeks after the diagnosis of IPA was reported to
be related to poor prognosis in IPA patients, too [19]. In




























































p-value 0.015 0.001 0.004 0.164 0.060 0.009 0.032 0.553 NA
GMI positivity Survival group
(n = 30)
13 (43.3) 12 (42.9) 10 (40.0) 7 (35.0) 5 (33.3) 1 (6.7) 2 (14.3) 3 (27.3) 2 (11.8)
Fatality group
(n = 15)
11 (73.3) 10 (76.9) 10 (83.3) 5 (55.6) 4 (44.4) 4 (57.1) 2 (66.7) 1 (50.0) NA
p-value 0.057 0.042 0.013 0.422 0.678 0.021 0.121 1.000 NA
GMI galactomannan index, NA not available
Fig. 3 Trends of serum galactomannan indices during antifungal therapy in the fatality group
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the present study, serum GMI 1 week after antifungal
therapy exhibited the most significant relationship with
mortality, and a significantly higher number of cases in
the fatality group showed positive GMI results compared
with those in the survival group at that time. In particular,
serum GMI of 1.5 or higher at 1 week after antifungal
therapy exhibited 72.7 % of PPV predicting mortality
within 12 weeks of antifungal therapy. If we put together
the result of the present study and previously reported re-
sults, reduction of serum GMI in the early phase of anti-
fungal therapy, especially in 1 or 2 weeks of antifungal
therapy, should be associated with improving prognosis in
IPA patients. The level of serum GMI was significantly as-
sociated with the degree of fungal burden of Aspergillus
species in the lung, and appropriate antifungal therapy de-
creased serum GMI levels and increased survival rate in
animal models [34–36]. Persistently positive serum GMI
despite antifungal therapy represents persisting fungal
burden and continuous fungal infection. This could be
caused by more suppressed immunity of the fatality
group compared with the survival group, considering
more children in the fatality group received palliative
care for uncontrolled underlying malignancies and ex-
perienced prolonged neutropenia. Also, this may mean
inadequacy of the administered antifungal therapy. In
particular, the association between mortality and the trend
of serum GMIs in the early phase of antifungal therapy
suggests the importance of administering appropriate
first-line antifungal agents. Therefore, empirical antifungal
therapy using the most effective antifungal agent against
IPA in immunocompromised patients should be necessary
in order to improve outcomes in those patients.
Voriconazole showed significant reduction of mortality
in IPA patients compared with previously used amphoteri-
cin B deoxycholate [8], and it is currently recommended
as the drug of choice for IPA [12, 37]. However, voricona-
zole therapy has still exhibited a mortality of 30 %. For
IPA patients at high risk of mortality, who show a high
serum GMI after 1 week of antifungal therapy, more in-
tensive antifungal therapy, such as antifungal combination
and higher dose of antifungal agents, may be considered
in order to improve outcomes. Several studies showed an
increased survival rate in children with IA treated with
voriconazole or liposomal amphotericin B in combination
with caspofungin compared with its monotherapy, other
studies showed that the efficacy and safety were not sig-
nificantly improved with antifungal combination therapy;
further, prospective controlled studies on antifungal com-
bination therapy in children have not been published [38].
However, a recently reported randomized trial showed a
lower 6-week mortality in adults with IPA receiving vori-
conazole and anidulafungin compared with those receiv-
ing voriconazole monotherapy, although the difference
was not statistically significant [39]. High dose liposomal
amphotericin B (10 mg/kg/day) did not induce a signifi-
cant reduction of mortality compared to 3 mg/kg/day of
liposomal amphotericin B monotherapy or in combination
with caspofungin [40, 41]. High dose voriconazole therapy
seems not to be useful because it has a narrow therapeutic
window and its adverse effects are associated with a high
serum drug level [42]. However, a higher dose of voricona-
zole is usually necessary in children than in adults [37];
therefore, appropriate dose adjustment of voriconazole
under close therapeutic drug monitoring (TDM) should
be performed to achieve proper therapeutic efficacy, espe-
cially in children with IPA. Further studies should be con-
ducted in the future to determine measures for improving
the therapeutic efficacy of antifungal therapy.
This study has several limitations arising from its
retrospective nature. GMI tests for BAL fluid samples
were performed only during the first 2 years of the study
period because of restriction from the government regula-
tions of the Korean National Health Assurance system.
Some patients with a negative serum GMI might test posi-
tive for BAL fluid GMI, and these might not be considered
in the last 3 years of the study. Piperacillin/tazobactam and
isepamicin have been administered as empirical antibiotics
for febrile neutropenia in our hospital, and therefore, some
children might show falsely positive serum GMI. In the
present study, 21.6 % of the cases with positive serum GMI
received piperacillin/tazobactam within 3 days before iden-
tifying positive serum GMI results, and 50.0 % of the cases
without positive serum GMI had received piperacillin/
tazobactam during repeated serum GMI tests. The fre-
quency of receiving piperacillin/tazobactam on the diag-
nosis of IPA was not significantly different between the
cases with and without positive serum GMI. The effect of
falsely positive serum GMI due to the administration of
piperacillin/tazobactam may be negligible in the present
study. Most cases in the present study received amphoteri-
cin B deoxycholate as a first-line antifungal agent due to
the government regulation based on the National Health
Assurance policy. In other institutions using antifungal
agents other than amphotericin B deoxycholate as a first-
line antifungal drug, the results of the present study may
not be applicable. However, Koo et al. reported that the
early decrease in serum GMI was associated with reduced
mortality when most patients received caspofungin or vor-
iconazole therapy [33].
Conclusions
In the present study, the outcome of immunocomprom-
ised children with IPA was significantly associated with
the early trend of serum GMIs during antifungal ther-
apy. Therefore, empirically administered antifungal
agents in immunocompromised patients at risk of IPA
should be fully effective against IPA in order to improve
their clinical outcome. In addition, IPA patients at high
Han et al. BMC Infectious Diseases  (2015) 15:271 Page 8 of 10
risk for mortality, who show a persistently high level of
serum GMI within 1 week of antifungal therapy, should
receive more intensive antifungal therapy.
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